# EDGAR Filing Document

**Accession Number:** 0000786947
**File Stem:** 0001104659-25-114929
**Filing Date:** 2025-11
**Character Count:** 7342
**Document Hash:** 51ea23b36398d34fc4eee8168dfbb1bb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-114929.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0001104659-25-114929

**CONFORMED SUBMISSION TYPE**: NT 10-Q

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251121

**DATE AS OF CHANGE**: 20251121

**EFFECTIVENESS DATE**: 20251121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACURA PHARMACEUTICALS, INC
- **CENTRAL INDEX KEY:** 0000786947
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 110853640
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-10113
- **FILM NUMBER:** 251507097

**BUSINESS ADDRESS:**
- **STREET 1:** 616 N. NORTH COURT, SUITE 120
- **CITY:** PALATINE
- **STATE:** IL
- **ZIP:** 60067
- **BUSINESS PHONE:** 847-705-7709

**MAIL ADDRESS:**
- **STREET 1:** 616 N. NORTH COURT, SUITE 120
- **STREET 2:** .
- **CITY:** PALATINE
- **STATE:** IL
- **ZIP:** 60067

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HALSEY DRUG CO INC/NEW
- **DATE OF NAME CHANGE:** 19920703

---

| | | |
|:---|:---|:---|
|  | OMB APPROVAL | OMB APPROVAL |
| **UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549** | OMB Number: | 3235-0058 |
| **UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549** | Expires: | September 30, 2028 |
| **UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549** | Estimated average burden hours per response. | 2.50 |

---

---

| | |
|:---|:---|
| **FORM 12b-25** | SEC FILE NUMBER |
| **FORM 12b-25** | 1-10113 |
|  | CUSIP NUMBER |
| **NOTIFICATION OF LATE FILING** | 00509L 802 |

---

*(Check one):* ◻ Form 10-K ◻ Form 20-F ◻ Form 11-K [√ ] Form 10-Q ◻ Form 10-D ◻ Form N-CEN ◻ Form N-CSR

---

| | |
|:---|:---|
| For Period Ended: September 30, 2025 | For Period Ended: September 30, 2025 |
| ◻ | Transition Report on Form 10-K |
| ◻ | Transition Report on Form 20-F |
| ◻ | Transition Report on Form 11-K |
| ◻ | Transition Report on Form 10-Q |
| For the Transition Period Ended: ____________________ | For the Transition Period Ended: ____________________ |

---

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

---

| |
|:---|
| ACURA PHARMACEUTICALS INC |
| Full Name of Registrant |
| N/A |
| Former Name if Applicable |
| 616 N. NORTH COURT |
| Address of Principal Executive Office *(Street and Number)* |
| PALATINE, IL 60067 |
| City, State and Zip Code |

---

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

---

| | | |
|:---|:---|:---|
| [√] | (a) | The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense; |
| [√] | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| [√] | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

---

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 will not be filed within the prescribed time period because of the Company's liquidity including the Company's ability to meet day-to-day operation obligations. We continue to work on finding funding solutions and are dependent on the receipt of loans from Abuse Deterrent Pharma, LLC, which are used to meet day-to-day operation obligations, although no assurance can be made that the receipt of such loans will continue or be sufficient to meet long-term day-to-day operation obligations. We have not filed our Annual Reports for the year ended December 31, 2024, 2023 nor 2022. We have not filed our Quarterly Reports for any of the quarterly periods in our fiscal year of 2024, 2023 or 2022. We have not filed our Quarterly Report for the quarterly period ended June 30, 2025 nor March 31, 2025. We continue to delay our public accounting firm's review services of each of our 2022, 2023, 2024 and 2025 quarterly results and their audit services of each of our 2022, 2023 and 2024 annual results, pending finding funding solutions and/or the receipt of loans from Abuse Deterrent Pharma, LLC; which may meet day-to-day operation obligations on a longer term basis. We cannot provide nor can any assurance can be given that the Company will be successful in filing any of the above mentioned reports or securing any funding solutions. The Company assumes no duty to update the status of the annual audits or quarterly reviews until the Annual Reports and the Quarterly Reports are filed with the SEC.

**PART IV — OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

ROBERT A. SEISER 847 705-7709 <br> (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities
 Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period
 that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ◻ Yes [√] No

---

| | |
|:---|:---|
|  | The Quarterly Report for the quarterly period ended September 30, 2025 will not be filed on time. The Quarterly Report for the quarterly periods ending June 30, 2025 or March 31, 2025 have not been field. Each of the quarterly reports for the periods ending September 30, June 30, and March 31, in each of the years ended 2024, 2023, and 2022 have not been filed. The Annual Report for each of the annual periods ended December 31, 2024, 2023 and 2022 have not been filed. |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |
|  | ◻ Yes [√] No |
|  | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |

---

<u>ACURA PHARMACEUTICALS INC</u>

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | NOVEMBER 21, 2025 | By: | /s/ ROBERT A. SEISER, SVP & CFO |

---